Selected research
Industry Research
NK1 Receptor Antagonist Industry Research Report 2026
Market perspective
The global NK1 Receptor Antagonist market was valued at US$ million in 2025 and is projected to reach US$ million by 2032, implying a CAGR of % over 2026–2032.
North America: the NK1 Receptor Antagonist market is projected to increase from US$ million in 2026 to US$ million by 2032, reflecting a CAGR of % over 2026–2032. Europe: the NK1 Receptor Antagonist market is projected to rise from US$ million in 2026 to US$ million by 2032, registering a CAGR of % over 2026–2032. Asia Pacific: the NK1 Receptor Antagonist market is expected to grow from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026–2032. Leading global service providers of NK1 Receptor Antagonist include Glenmark, Heron Therapeutics, TerSera Therapeutics, Torrent Pharmaceuticals, Beijing Sihuan Pharmaceutical, Fresenius Kabi, Hansoh Pharma, Helsinn Healthcare and Jiangsu Hengrui Pharmaceuticals, among others; in 2025, the top three vendors together accounted for approximately % of global revenue.
Report Scope
Read the full market overview
This report quantifies the global NK1 Receptor Antagonist market in terms of revenue (US$ million) and, where applicable, service volume (k units), using 2024 as the base year and providing annual historical and forecast data for 2021–2032.
It standardizes definitions of service Types and end-use Applications, harmonizes provider attribution, and delivers comparable time series by company, Type, Application, and region/country, including indicative price bands (US$/k units) and concentration ratios (CR5/CR10). Outputs are intended to support service design, budgeting, capacity planning, and benchmarking for providers, platforms, channel partners, and investors; the report also reviews technology shifts and notable service innovations relevant to NK1 Receptor Antagonist.
Key Companies & Market Share Insights
This section profiles leading service providers with 2021–2025 results and a 2026–2032 outlook—covering revenue, market share, price bands, service portfolio and client mix, regional and channel mix, and key developments (M&A, network expansion, certifications). It also provides global revenue, average price, and—where applicable—volume metrics by provider, and calculates CR5/CR10 and rank changes to support comparative benchmarking.
NK1 Receptor Antagonist Market by Company
Glenmark
Heron Therapeutics
TerSera Therapeutics
Torrent Pharmaceuticals
Beijing Sihuan Pharmaceutical
Fresenius Kabi
Hansoh Pharma
Helsinn Healthcare
Jiangsu Hengrui Pharmaceuticals
Luoxin Pharmaceutical
Merck
Qilu Pharmaceutical
Yichang Humanwell Pharmaceutical
Chia Tai Tianqing Pharmaceutical
NK1 Receptor Antagonist Segment by Type
Netupitant
Maropitant
Rolapitant
Fosaprepitant
Aprepitant
Other
NK1 Receptor Antagonist Segment by Application
Hospital
Specialty Clinic
NK1 Receptor Antagonist Segment by Region
North America
United States
Canada
Mexico
Europe
Germany
France
U.K.
Italy
Spain
Russia
Netherlands
Nordic Countries
Asia-Pacific
China
Japan
South Korea
India
Australia
Taiwan
Southeast Asia
South America
Brazil
Argentina
Chile
Middle East & Africa
Saudi Arabia
Israel
United Arab Emirates
Turkey
Iran
Egypt
Key Drivers & Barriers
High-impact rendering factors and drivers have been studied in this report to aid the readers to understand the general development. Moreover, the report includes restraints and challenges that may act as stumbling blocks on the way of the players. This will assist the users to be attentive and make informed decisions related to business. Specialists have also laid their focus on the upcoming business prospects.
Reasons to Buy This Report
1. This report will help the readers to understand the competition within the industries and strategies for the competitive environment to enhance the potential profit. The report also focuses on the competitive landscape of the global NK1 Receptor Antagonist market, and introduces in detail the market share, industry ranking, competitor ecosystem, market performance, new product development, operation situation, expansion, and acquisition. etc. of the main players, which helps the readers to identify the main competitors and deeply understand the competition pattern of the market.
2. This report will help stakeholders to understand the global industry status and trends of NK1 Receptor Antagonist and provides them with information on key market drivers, restraints, challenges, and opportunities.
3. This report will help stakeholders to understand competitors better and gain more insights to strengthen their position in their businesses. The competitive landscape section includes the market share and rank (in volume and value), competitor ecosystem, new product development, expansion, and acquisition.
4. This report stays updated with novel technology integration, features, and the latest developments in the market
5. This report helps stakeholders to gain insights into which regions to target globally
6. This report helps stakeholders to gain insights into the end-user perception concerning the adoption of NK1 Receptor Antagonist.
7. This report helps stakeholders to identify some of the key players in the market and understand their valuable contribution.
Chapter Outline
Chapter 1: Research objectives, research methods, data sources, data cross-validation;
Chapter 2: Introduces the report scope of the report, executive summary of different market segments (product type, application, etc), including the market size of each market segment, future development potential, and so on. It offers a high-level view of the current state of the market and its likely evolution in the short to mid-term, and long term.
Chapter 3: Provides the analysis of various market segments product types, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.
Chapter 4: Provides the analysis of various market segments application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.
Chapter 5: Introduces executive summary of global market size, regional market size, this section also introduces the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by companies in the industry, and the analysis of relevant policies in the industry.
Chapter 6: Detailed analysis of NK1 Receptor Antagonist companies’ competitive landscape, revenue market share, latest development plan, merger, and acquisition information, etc.
Chapter 7, 8, 9, 10, 11: North America, Europe, Asia Pacific, South America, Middle East and Africa segment by country. It provides a quantitative analysis of the market size and development potential of each region and its main countries and introduces the market development, future development prospects, market space, and capacity of each country in the world.
Chapter 12: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including revenue, gross margin, product introduction, recent development, etc.
Chapter 13: The main points and conclusions of the report.
More report detail
Tables and figures
Scope & coverage.
Types
- Netupitant
- Maropitant
- Rolapitant
- Fosaprepitant
- Aprepitant
- Other
Applications
- Hospital
- Specialty Clinic
Companies covered
- Glenmark
- Heron Therapeutics
- TerSera Therapeutics
- Torrent Pharmaceuticals
- Beijing Sihuan Pharmaceutical
- Fresenius Kabi
- Hansoh Pharma
- Helsinn Healthcare
- Jiangsu Hengrui Pharmaceuticals
- Luoxin Pharmaceutical
- Merck
- Qilu Pharmaceutical
- Yichang Humanwell Pharmaceutical
- Chia Tai Tianqing Pharmaceutical
Inside the report.
1 Preface
- 1.1 Scope of Report
- 1.2 Reasons for Doing This Study
- 1.3 Research Methodology
- 1.4 Research Process
- 1.5 Data Source
- 1.5.1 Secondary Sources
- 1.5.2 Primary Sources
2 Market Overview
- 2.1 Product Definition
- 2.2 NK1 Receptor Antagonist by Type
- 2.2.1 Market Value Comparison by Type (2021 VS 2025 VS 2032)
- 2.2.2 Netupitant
- 2.2.3 Maropitant
- 2.2.4 Rolapitant
- 2.2.5 Fosaprepitant
- 2.2.6 Aprepitant
- 2.2.7 Other
- 2.3 NK1 Receptor Antagonist by Application
- 2.3.1 Market Value Comparison by Application (2021 VS 2025 VS 2032)
- 2.3.2 Hospital
- 2.3.3 Specialty Clinic
- 2.4 Assumptions and Limitations
3 NK1 Receptor Antagonist Breakdown Data by Type
- 3.1 Global NK1 Receptor Antagonist Historic Market Size by Type (2021-2026)
- 3.2 Global NK1 Receptor Antagonist Forecasted Market Size by Type (2027-2032)
4 NK1 Receptor Antagonist Breakdown Data by Application
- 4.1 Global NK1 Receptor Antagonist Historic Market Size by Application (2021-2026)
- 4.2 Global NK1 Receptor Antagonist Forecasted Market Size by Application (2027-2032)
5 Global Growth Trends
- 5.1 Global NK1 Receptor Antagonist Market Perspective (2021-2032)
- 5.2 Global NK1 Receptor Antagonist Growth Trends by Region
- 5.2.1 Global NK1 Receptor Antagonist Market Size by Region: 2021 VS 2025 VS 2032
- 5.2.2 NK1 Receptor Antagonist Historic Market Size by Region (2021-2026)
- 5.2.3 NK1 Receptor Antagonist Forecasted Market Size by Region (2027-2032)
- 5.3 NK1 Receptor Antagonist Market Dynamics
- 5.3.1 NK1 Receptor Antagonist Industry Trends
- 5.3.2 NK1 Receptor Antagonist Market Drivers
- 5.3.3 NK1 Receptor Antagonist Market Challenges
- 5.3.4 NK1 Receptor Antagonist Market Restraints
6 Market Competitive Landscape by Players
- 6.1 Global Top NK1 Receptor Antagonist Players by Revenue
- 6.1.1 Global Top NK1 Receptor Antagonist Players by Revenue (2021-2026)
- 6.1.2 Global NK1 Receptor Antagonist Revenue Market Share by Players (2021-2026)
- 6.2 Global NK1 Receptor Antagonist Industry Players Ranking, 2023 VS 2024 VS 2025
- 6.3 Global Key Players of NK1 Receptor Antagonist Head Office and Area Served
- 6.4 Global NK1 Receptor Antagonist Players, Product Type & Application
- 6.5 Global NK1 Receptor Antagonist Manufacturers Established Date
- 6.6 Global NK1 Receptor Antagonist Market CR5 and HHI
- 6.7 Global Players Mergers & Acquisition
7 North America
- 7.1 North America NK1 Receptor Antagonist Market Size (2021-2032)
- 7.2 North America NK1 Receptor Antagonist Market Growth Rate by Country: 2021 VS 2025 VS 2032
- 7.3 North America NK1 Receptor Antagonist Market Size by Country (2021-2026)
- 7.4 North America NK1 Receptor Antagonist Market Size by Country (2027-2032)
- 7.5 United States
- 7.5 United States
- 7.6 Canada
- 7.7 Mexico
8 Europe
- 8.1 Europe NK1 Receptor Antagonist Market Size (2021-2032)
- 8.2 Europe NK1 Receptor Antagonist Market Growth Rate by Country: 2021 VS 2025 VS 2032
- 8.3 Europe NK1 Receptor Antagonist Market Size by Country (2021-2026)
- 8.4 Europe NK1 Receptor Antagonist Market Size by Country (2027-2032)
- 8.5 Germany
- 8.6 France
- 8.7 U.K.
- 8.8 Italy
- 8.9 Spain
- 8.10 Russia
- 8.11 Netherlands
- 8.12 Nordic Countries
9 Asia-Pacific
- 9.1 Asia-Pacific NK1 Receptor Antagonist Market Size (2021-2032)
- 9.2 Asia-Pacific NK1 Receptor Antagonist Market Growth Rate by Country: 2021 VS 2025 VS 2032
- 9.3 Asia-Pacific NK1 Receptor Antagonist Market Size by Country (2021-2026)
- 9.4 Asia-Pacific NK1 Receptor Antagonist Market Size by Country (2027-2032)
- 9.5 China
- 9.6 Japan
- 9.7 South Korea
- 9.8 India
- 9.9 Australia
- 9.10 China Taiwan
- 9.11 Southeast Asia
10 South America
- 10.1 South America NK1 Receptor Antagonist Market Size (2021-2032)
- 10.2 South America NK1 Receptor Antagonist Market Growth Rate by Country: 2021 VS 2025 VS 2032
- 10.3 South America NK1 Receptor Antagonist Market Size by Country (2021-2026)
- 10.4 South America NK1 Receptor Antagonist Market Size by Country (2027-2032)
- 10.5 Brazil
- 10.6 Argentina
- 10.7 Chile
- 10.8 Colombia
- 10.9 Peru
11 Middle East & Africa
- 11.1 Middle East & Africa NK1 Receptor Antagonist Market Size (2021-2032)
- 11.2 Middle East & Africa NK1 Receptor Antagonist Market Growth Rate by Country: 2021 VS 2025 VS 2032
- 11.3 Middle East & Africa NK1 Receptor Antagonist Market Size by Country (2021-2026)
- 11.4 Middle East & Africa NK1 Receptor Antagonist Market Size by Country (2027-2032)
- 11.5 Saudi Arabia
- 11.6 Israel
- 11.7 United Arab Emirates
- 11.8 Turkey
- 11.9 Iran
- 11.10 Egypt
12 Players Profiled
- 12.1 Glenmark
- 12.1.1 Glenmark Company Information
- 12.1.2 Glenmark Business Overview
- 12.1.3 Glenmark Revenue in NK1 Receptor Antagonist Business (2021-2026)
- 12.1.4 Glenmark NK1 Receptor Antagonist Product Portfolio
- 12.1.5 Glenmark Recent Developments
- 12.2 Heron Therapeutics
- 12.2.1 Heron Therapeutics Company Information
- 12.2.2 Heron Therapeutics Business Overview
- 12.2.3 Heron Therapeutics Revenue in NK1 Receptor Antagonist Business (2021-2026)
- 12.2.4 Heron Therapeutics NK1 Receptor Antagonist Product Portfolio
- 12.2.5 Heron Therapeutics Recent Developments
- 12.3 TerSera Therapeutics
- 12.3.1 TerSera Therapeutics Company Information
- 12.3.2 TerSera Therapeutics Business Overview
- 12.3.3 TerSera Therapeutics Revenue in NK1 Receptor Antagonist Business (2021-2026)
- 12.3.4 TerSera Therapeutics NK1 Receptor Antagonist Product Portfolio
- 12.3.5 TerSera Therapeutics Recent Developments
- 12.4 Torrent Pharmaceuticals
- 12.4.1 Torrent Pharmaceuticals Company Information
- 12.4.2 Torrent Pharmaceuticals Business Overview
- 12.4.3 Torrent Pharmaceuticals Revenue in NK1 Receptor Antagonist Business (2021-2026)
- 12.4.4 Torrent Pharmaceuticals NK1 Receptor Antagonist Product Portfolio
- 12.4.5 Torrent Pharmaceuticals Recent Developments
- 12.5 Beijing Sihuan Pharmaceutical
- 12.5.1 Beijing Sihuan Pharmaceutical Company Information
- 12.5.2 Beijing Sihuan Pharmaceutical Business Overview
- 12.5.3 Beijing Sihuan Pharmaceutical Revenue in NK1 Receptor Antagonist Business (2021-2026)
- 12.5.4 Beijing Sihuan Pharmaceutical NK1 Receptor Antagonist Product Portfolio
- 12.5.5 Beijing Sihuan Pharmaceutical Recent Developments
- 12.6 Fresenius Kabi
- 12.6.1 Fresenius Kabi Company Information
- 12.6.2 Fresenius Kabi Business Overview
- 12.6.3 Fresenius Kabi Revenue in NK1 Receptor Antagonist Business (2021-2026)
- 12.6.4 Fresenius Kabi NK1 Receptor Antagonist Product Portfolio
- 12.6.5 Fresenius Kabi Recent Developments
- 12.7 Hansoh Pharma
- 12.7.1 Hansoh Pharma Company Information
- 12.7.2 Hansoh Pharma Business Overview
- 12.7.3 Hansoh Pharma Revenue in NK1 Receptor Antagonist Business (2021-2026)
- 12.7.4 Hansoh Pharma NK1 Receptor Antagonist Product Portfolio
- 12.7.5 Hansoh Pharma Recent Developments
- 12.8 Helsinn Healthcare
- 12.8.1 Helsinn Healthcare Company Information
- 12.8.2 Helsinn Healthcare Business Overview
- 12.8.3 Helsinn Healthcare Revenue in NK1 Receptor Antagonist Business (2021-2026)
- 12.8.4 Helsinn Healthcare NK1 Receptor Antagonist Product Portfolio
- 12.8.5 Helsinn Healthcare Recent Developments
- 12.9 Jiangsu Hengrui Pharmaceuticals
- 12.9.1 Jiangsu Hengrui Pharmaceuticals Company Information
- 12.9.2 Jiangsu Hengrui Pharmaceuticals Business Overview
- 12.9.3 Jiangsu Hengrui Pharmaceuticals Revenue in NK1 Receptor Antagonist Business (2021-2026)
- 12.9.4 Jiangsu Hengrui Pharmaceuticals NK1 Receptor Antagonist Product Portfolio
- 12.9.5 Jiangsu Hengrui Pharmaceuticals Recent Developments
- 12.10 Luoxin Pharmaceutical
- 12.10.1 Luoxin Pharmaceutical Company Information
- 12.10.2 Luoxin Pharmaceutical Business Overview
- 12.10.3 Luoxin Pharmaceutical Revenue in NK1 Receptor Antagonist Business (2021-2026)
- 12.10.4 Luoxin Pharmaceutical NK1 Receptor Antagonist Product Portfolio
- 12.10.5 Luoxin Pharmaceutical Recent Developments
- 12.11 Merck
- 12.11.1 Merck Company Information
- 12.11.2 Merck Business Overview
- 12.11.3 Merck Revenue in NK1 Receptor Antagonist Business (2021-2026)
- 12.11.4 Merck NK1 Receptor Antagonist Product Portfolio
- 12.11.5 Merck Recent Developments
- 12.12 Qilu Pharmaceutical
- 12.12.1 Qilu Pharmaceutical Company Information
- 12.12.2 Qilu Pharmaceutical Business Overview
- 12.12.3 Qilu Pharmaceutical Revenue in NK1 Receptor Antagonist Business (2021-2026)
- 12.12.4 Qilu Pharmaceutical NK1 Receptor Antagonist Product Portfolio
- 12.12.5 Qilu Pharmaceutical Recent Developments
- 12.13 Yichang Humanwell Pharmaceutical
- 12.13.1 Yichang Humanwell Pharmaceutical Company Information
- 12.13.2 Yichang Humanwell Pharmaceutical Business Overview
- 12.13.3 Yichang Humanwell Pharmaceutical Revenue in NK1 Receptor Antagonist Business (2021-2026)
- 12.13.4 Yichang Humanwell Pharmaceutical NK1 Receptor Antagonist Product Portfolio
- 12.13.5 Yichang Humanwell Pharmaceutical Recent Developments
- 12.14 Chia Tai Tianqing Pharmaceutical
- 12.14.1 Chia Tai Tianqing Pharmaceutical Company Information
- 12.14.2 Chia Tai Tianqing Pharmaceutical Business Overview
- 12.14.3 Chia Tai Tianqing Pharmaceutical Revenue in NK1 Receptor Antagonist Business (2021-2026)
- 12.14.4 Chia Tai Tianqing Pharmaceutical NK1 Receptor Antagonist Product Portfolio
- 12.14.5 Chia Tai Tianqing Pharmaceutical Recent Developments
13 Report Conclusion
14 Disclaimer
GET THE RESEARCH
Choose your license.
Choose who needs access.
All options are for this report and research series.
PDF by email within 3–5 working days after payment confirmation.
Talk to an analyst